IP Library Patent Application 19262944
Patent Application
App. No. 19/262,944

ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED ALPHA-SYNUCLEIN AGGREGATES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
19/262,944
Abstract

The present specification provides a monoclonal antibody that specifically binds aggregated, non-phosphorylated α-synuclein and a hybridoma producing it. Also disclosed are methods of generating antibodies that specifically binds aggregated, non-phosphorylated α-synuclein and uses thereof. Uses of anti-α-synuclein antibody in detection and diagnostic assays, and for prophylaxis or therapy of α-synuclein-associated neurodegenerative diseases, are also disclosed.

Claims (16)

1 . A nucleic acid molecule comprising a sequence encoding a monoclonal antibody that specifically binds aggregated, non-phosphorylated α-synuclein comprising a heavy chain variable region (VH) and a light chain variable region (VL).

2 . A host cell comprising the nucleic acid molecule of claim 1 , wherein the host cell is capable of expressing the monoclonal antibody.

3 . The host cell of claim 2 , wherein the nucleic acid molecule encoding the monoclonal antibody is integrated into host cell genomic DNA.

4 . A vector comprising the nucleic acid molecule of claim 1 .

5 . A host cell comprising the nucleic acid molecule of claim 1 , wherein the host cell is capable of replicating the nucleic acid molecule.

6 . The nucleic acid molecule of claim 1 , wherein the sequence encoding the monoclonal antibody is cDNA.

7 . The nucleic acid molecule of claim 1 , wherein the sequence encoding the monoclonal antibody is mRNA.

8 . A nucleic acid molecule comprising a sequence encoding the monoclonal antibody of claim 7 .

9 . A host cell comprising the nucleic acid molecule of claim 8 , wherein the host cell is capable of expressing the monoclonal antibody.

10 . The host cell of claim 9 , wherein the nucleic acid molecule encoding the monoclonal antibody is integrated into host cell genomic DNA.

11 . A vector comprising the nucleic acid molecule of claim 8 .

12 . A host cell comprising the nucleic acid molecule of claim 8 , wherein the host cell is capable of replicating the nucleic acid molecule.

13 . The nucleic acid molecule of claim 8 , wherein the sequence encoding the monoclonal antibody is cDNA.

14 . The nucleic acid molecule of claim 8 , wherein the sequence encoding the monoclonal antibody is mRNA.

15 . An immunoassay for the detection or quantitation of aggregated, non-phosphorylated α-synuclein comprising a step for contacting a sample with the monoclonal antibody of claim 1 .

16 . A method of treating an α-synuclein-associated neurodegenerative disorder comprising administering the anti-α-synuclein antibody of claim 1 to a subject in need thereof.